Cinepazide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Cinepazide
- DrugBank Accession Number
- DB12123
- Background
Cinepazide has been used in trials studying the treatment of Ischemic Stroke.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 417.506
Monoisotopic: 417.22637111 - Chemical Formula
- C22H31N3O5
- Synonyms
- Cinepazide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareIloprost Iloprost may increase the hypotensive activities of Cinepazide. Isosorbide mononitrate Cinepazide may increase the vasodilatory activities of Isosorbide mononitrate. Patent Blue The therapeutic efficacy of Cinepazide can be decreased when used in combination with Patent Blue. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Cinepazide Maleate Y35B3VA60V 26328-04-1 XSTJTOKYCAJVMJ-GVTSEVKNSA-N
Categories
- ATC Codes
- C04AX27 — Cinepazide
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cinnamic acids and derivatives. These are organic aromatic compounds containing a benzene and a carboxylic acid group (or a derivative thereof) forming 3-phenylprop-2-enoic acid.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Cinnamic acids and derivatives
- Sub Class
- Not Available
- Direct Parent
- Cinnamic acids and derivatives
- Alternative Parents
- Alpha amino acids and derivatives / N-piperazineacetamides / Anisoles / Styrenes / Phenoxy compounds / Methoxybenzenes / N-acylpyrrolidines / Alkyl aryl ethers / N-alkylpiperazines / Tertiary carboxylic acid amides show 6 more
- Substituents
- 1,4-diazinane / Alkyl aryl ether / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carbonyl group show 25 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 67Y4P5C84X
- CAS number
- 23887-46-9
- InChI Key
- RCUDFXMNPQNBDU-VOTSOKGWSA-N
- InChI
- InChI=1S/C22H31N3O5/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24/h6-7,14-15H,4-5,8-13,16H2,1-3H3/b7-6+
- IUPAC Name
- (2E)-1-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazin-1-yl}-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
- SMILES
- COC1=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=CC(OC)=C1OC
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5282459
- PubChem Substance
- 347828422
- ChemSpider
- 4445611
- ChEBI
- 135676
- ChEMBL
- CHEMBL1874750
- ZINC
- ZINC000036379005
- Wikipedia
- Cinepazide
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Ischemic Stroke 1 somestatus stop reason just information to hide 2 Completed Treatment Acute Ischemic Stroke 1 somestatus stop reason just information to hide 2 Unknown Status Treatment Ischemic Stroke 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.502 mg/mL ALOGPS logP 1.67 ALOGPS logP 0.67 Chemaxon logS -2.9 ALOGPS pKa (Strongest Basic) 5.91 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 71.55 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 115.36 m3·mol-1 Chemaxon Polarizability 46.39 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0005900000-83c06e16463a17008bd5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00kb-3831900000-3e426c08b0574e9094c7 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-4114900000-65b1bd04952b67cb2d05 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0g30-0409300000-78e124930a70cde7d121 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0100-3958300000-1548a008da6513a47de7 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-05dr-0729000000-7e168e734ce2865469f5 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 199.15413 predictedDeepCCS 1.0 (2019) [M+H]+ 201.51213 predictedDeepCCS 1.0 (2019) [M+Na]+ 208.31227 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:23 / Updated at February 21, 2021 18:53